A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for the Treatment of Participants With Pulmonary Arterial Hypertension (Part B)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for the Treatment of Participants With Pulmonary Arterial Hypertension (Part B)
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
The CLTP001A12202 study will explore the safety, tolerability, and pharmacokinetics of LTP001 in healthy volunteers (Part A) and will evaluate the safety and efficacy (Part B) followed by safety extension in participants with pulmonary arterial hypertension.
Part A Inclusion Criteria:
Part A Exclusion Criteria:
Part B Inclusion Criteria:
-Confirmed diagnosis of PAH, pre-randomization PVR ≥400 dyn.sec.cm-5, treatment with stable doses of standard-of-care PAH therapies, 6-minute walk distance ≥ 150 m and ≤450 m.
Part B Exclusion Criteria:
Any surgical or medical condition which may place the participant at higher risk from his/her participation in the study Women of child-bearing potential unless they are using highly effective methods of contraception Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 24 hours after stopping study treatment.
History of hypersensitivity to any of the study treatments or excipients
Other protocol-defined inclusion / exclusion criteria may apply
novartis.email@novartis.com1-888-669-6682
+41613241111
Scottsdale, Arizona 85258, United States
+1 602 271 0832
Ridgeland, Mississippi 39157-5179, United States
CABA, C1426ABP, Argentina
Santiago Compostela, A Coruna 15706, Spain
Las Palmas de Gran C, Las Palmas 35016, Spain
+1 714 456 6037
+1 650 725 5495
+1 720 848 6567
+1 407 841 1100
+1 813 844 7137
+1 404 778 3261
+1 913 588 9722
+1 502 587 8000
+1 617 636 4288
+1 781 744 3874
+1 941 924 9800
+1 512 447 2985
+1 214 645 6488
+1 801 213 4086
+1 804 288 5945